As the Translational and Biomarker Lead at Bristol Myers Squibb, Satya Pathi plays a pivotal role in bridging the gap between early-stage oncology drug discovery and clinical application. With over 12 years of dedicated experience in oncology, Satya has successfully advanced numerous new molecular entities...
As the Translational and Biomarker Lead at Bristol Myers Squibb, Satya Pathi plays a pivotal role in bridging the gap between early-stage oncology drug discovery and clinical application. With over 12 years of dedicated experience in oncology, Satya has successfully advanced numerous new molecular entities from the initial discovery phase to clinical proof of concept, demonstrating a robust understanding of the complexities involved in drug development. His expertise encompasses target identification and validation, as well as a deep comprehension of mechanisms of action and resistance, which are critical for developing effective therapeutic strategies.
In his current role, Satya is instrumental in designing mechanism-of-action (MoA)-based clinical translational plans that guide indication selection and the development of predictive and pharmacodynamics biomarkers. His proficiency in managing projects with Contract Research Organizations (CROs) for clinical biomarker assay development ensures that Bristol Myers Squibb remains at the forefront of innovative oncology solutions. Additionally, Satya excels in developing target engagement and peripheral pharmacodynamic assays for First-in-Human studies, which are essential for assessing the efficacy and safety of novel therapies.
A strong collaborator, Satya leverages his skills in digital pathology, flow cytometry, and cell biology to foster cross-functional partnerships that enhance research outcomes. His ability to synthesize complex datasets and communicate findings effectively through presentations and reports further solidifies his role as a key contributor to Bristol Myers Squibb's oncology and immuno-oncology portfolio. As he continues to push the boundaries of translational science, Satya remains committed to improving patient outcomes through the development of groundbreaking cancer therapies.
